Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP7 | P09237 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28329064 | 1.00 | CYP1A2 (0.40) | CYP1A2ALOX5GABBR2GABBR1MMP1 | |
| SCHEMBL6219939 | 0.82 | CA2 (0.43) | CYP1A2ALOX5CA1CA2 | |
| SCHEMBL7164190 | 0.82 | CA2 (0.43) | CYP1A2ALOX5CA1CA2 | |
| SCHEMBL18317133 | 0.81 | GABBR2 (0.59) | CYP1A2GABBR2GABBR1MMP1MMP2 | |
| SCHEMBL28327838 | 0.80 | PARP1 (0.42) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL5217546 | 0.80 | TAAR1 (0.48) | — | |
| SCHEMBL5217923 | 0.80 | TAAR1 (0.48) | — | |
| SCHEMBL5217555 | 0.80 | TAAR1 (0.48) | — | |
| SCHEMBL18489396 | 0.78 | GABBR2 (0.34) | GABBR2GABBR1MMP2MMP9MMP13 | |
| SCHEMBL6033113 | 0.77 | GABBR2 (0.42) | CYP1A2ALOX5GABBR2GABBR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | CYP1A2 1833/4885ALOX5 1983/4885GABBR2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.